Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.

Harika Dasari, Bharath Wootla, Arthur E Warrington, Moses Rodriguez
{"title":"Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.","authors":"Harika Dasari,&nbsp;Bharath Wootla,&nbsp;Arthur E Warrington,&nbsp;Moses Rodriguez","doi":"10.4172/2329-9096.1000348","DOIUrl":null,"url":null,"abstract":"<p><p>We provide an overview of rehabilitation in neurological diseases. A large amount of literature available on neurorehabilitation is based from the rehabilitative work on stroke and spinal cord injuries. After a brief description of rehabilitation, the potential application of neurorehabilitation in neurodegenerative diseases specifically multiple sclerosis (MS) is summarized. Since MS causes a wide variety of symptoms, the rehabilitation in MS patients may benefit from an interdisciplinary approach that encloses physiotherapy, cognitive rehabilitation, psychological therapy, occupational therapy, and other methods to improve fatigue. Neurorehabilitation helps patients to reach and maintain their optimal physical, psychological and intellectual, levels but it does not reverse long-term disabilities that arise from neurological disorders. This calls for the need of better neuroregenerative and neuroprotective treatment strategies in addition to neurorehabilitation. We discuss neuroprotective drugs aimed at preventing axonal, neuronal, myelin and oligodendrocyte damage and cell death that are approved and others that are currently in clinical trials, with an emphasis on human derived natural antibodies with remyleination potential. Our investigative group developed recombinant natural human IgM antibodies against oligodendrocytes and neurons with a potential for CNS repair and remyleination. One such recombinant antibody, rHIgM22 completed a phase 1 clinical trial with no toxicity and with an objective of promoting remyleination in multiple sclerosis. Inclusion of these drugs as a multifaceted approach may further enhance the efficacy of neurorehabilitation in neuroinflammatory and neurodegenerative disorders.</p>","PeriodicalId":73470,"journal":{"name":"International journal of physical medicine & rehabilitation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-9096.1000348","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of physical medicine & rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-9096.1000348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/6/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

We provide an overview of rehabilitation in neurological diseases. A large amount of literature available on neurorehabilitation is based from the rehabilitative work on stroke and spinal cord injuries. After a brief description of rehabilitation, the potential application of neurorehabilitation in neurodegenerative diseases specifically multiple sclerosis (MS) is summarized. Since MS causes a wide variety of symptoms, the rehabilitation in MS patients may benefit from an interdisciplinary approach that encloses physiotherapy, cognitive rehabilitation, psychological therapy, occupational therapy, and other methods to improve fatigue. Neurorehabilitation helps patients to reach and maintain their optimal physical, psychological and intellectual, levels but it does not reverse long-term disabilities that arise from neurological disorders. This calls for the need of better neuroregenerative and neuroprotective treatment strategies in addition to neurorehabilitation. We discuss neuroprotective drugs aimed at preventing axonal, neuronal, myelin and oligodendrocyte damage and cell death that are approved and others that are currently in clinical trials, with an emphasis on human derived natural antibodies with remyleination potential. Our investigative group developed recombinant natural human IgM antibodies against oligodendrocytes and neurons with a potential for CNS repair and remyleination. One such recombinant antibody, rHIgM22 completed a phase 1 clinical trial with no toxicity and with an objective of promoting remyleination in multiple sclerosis. Inclusion of these drugs as a multifaceted approach may further enhance the efficacy of neurorehabilitation in neuroinflammatory and neurodegenerative disorders.

神经保护药物在多发性硬化症患者神经康复中的联合应用。
我们提供神经系统疾病康复的概述。大量关于神经康复的文献是基于中风和脊髓损伤的康复工作。在简要介绍康复后,总结了神经康复在神经退行性疾病特别是多发性硬化症(MS)中的潜在应用。由于多发性硬化症引起的症状多种多样,多发性硬化症患者的康复可能受益于跨学科的方法,包括物理治疗、认知康复、心理治疗、职业治疗等方法来改善疲劳。神经康复帮助患者达到并保持最佳的身体、心理和智力水平,但它不能逆转由神经系统疾病引起的长期残疾。这需要更好的神经再生和神经保护治疗策略,除了神经康复。我们讨论了旨在预防轴突、神经元、髓鞘和少突胶质细胞损伤和细胞死亡的神经保护药物,这些药物已被批准,其他药物目前正在临床试验中,重点是具有再聚酰基化潜力的人类来源的天然抗体。我们的研究小组开发了针对少突胶质细胞和神经元的重组天然人IgM抗体,具有中枢神经系统修复和再聚合的潜力。其中一种重组抗体rHIgM22完成了一期临床试验,无毒性,目的是促进多发性硬化症的再蛋白化。纳入这些药物作为一个多方面的方法可能进一步提高神经康复对神经炎症和神经退行性疾病的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信